New hope for preventing Parkinson’s disease
Researchers at Macquarie University have conducted a phase two clinical trial for an experimental drug, SNT-4728, which shows promise in reducing brain inflammation. The study focused on patients with a sleep disorder that often precedes Parkinson's disease, suggesting the drug could potentially slow or prevent the condition.
Why it matters
This represents a significant potential breakthrough in neurodegenerative disease prevention by targeting early-stage inflammation before cell death occurs.
Disclaimer: By joining, you agree to our Privacy Policy & Terms of Use
Are Media Pty Limited collects your personal information through this site to process registrations, send out newsletters, communicate offers, discounts, competitions, or surveys, and to provide you with targeted advertising based on your online activities. Our Privacy Policy contains information on how you can access or correct your personal information, which entities we may disclose your personal information to (including overseas recipients), how to opt out of targeted advertising, and how to lodge a complaint.
An Australian-led clinical trial has shown promising results for an experimental drug that could help delay or even prevent Parkinson's disease .
Researchers at Macquarie University tested a daily pill in people with a sleep disorder that can appear years before a Parkinson's diagnosis.
After 12 weeks, brain scans showed reduced inflammation in a region involved in controlling movement.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in